NCT00203424

Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib

A Phase II Trial of Adjuvant Bevacizumab and Erlotinib in Patients at High Risk for Early Relapse Following Radical Prostatectomy for Prostate Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 23 (actual)
• Sponsor: Translational Oncology Research International · Academic / Other
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and effectiveness of bevacizumab plus erlotinib following radical prostatectomy.

Detailed description

This study explores the anti-tumor activity of adjuvant bevacizumab plus erlotinib in a select group of prostate cancer patients deemed at high risk for early relapse following radical prostatectomy.

Conditions

• Prostate Cancer

Interventions

Type	Name	Description
DRUG	Erlotinib + Bevacizumab	Erlotinib every day for 24 weeks and Bevacizumab every 3 weeks for a total of 8 doses

Timeline

• Start date: 2006-01-01
• Primary completion: 2009-02-01
• Completion: 2010-06-01
• First posted: 2005-09-20
• Last updated: 2016-03-25
• Results posted: 2011-05-09

Locations

16 sites across 1 country: United States